Location: Birmingham
University of Alabama at Birmingham- Division of Preventive Medicine

Trial Title and Description:
Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)- The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Isabelle Joffrion
205-934-9502
ijoffrion@dopm.uab.edu

Back to Top

Location: Tuscaloosa
Tuscaloosa VA Medical Center- Nursing Home Care Unit (NHCU)

Trial Title and Description:
Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT)-
The purpose of this study is to determine whether a low dose of opiate pain medication is effective for the treatment of discomfort in patients with advanced dementia. The study medication is also known as Lortab and contains both a narcotic pain medication and the same pain medication as contained in Tylenol. The study will also assess how well patients tolerate this medication and will measure the impact that relief of discomfort has on agitation and other symptoms. This study is an eight-week long clinical trial for discomfort among veterans with advanced dementia who are admitted to a Nursing Home Care Unit (NHCU) at the Tuscaloosa VA Medical Center.

Enrollment Status: Not yet recruiting

Study Dates: Start: October 2006 Expected Completion: July 2009

Condition: Dementia, Pain, Alzheimer's disease, Vascular dementia
Age Eligibility: 55 and above
Gender Eligibility: Both
Enrollment Goal: 48
Clinical Identifier: NCT00385684
Study Phase: Phase 4
Study Type: Interventional

Sponsor: Department of Veterans Affairs

Contact Information:
Lori L. Davis
205-554-2000, ext. 3819

Julie R. Wakefield
205-554-2000, ext. 3674

Back to Top

Location: Anchorage
Alaska Regional Hospital

Trial Title and Description:
Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Judith Link
907-264-1579
judith.link@healthcare.com

Back to Top

Location: Anchorage
Providence Alaska Medical Center

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Kathleen W. Shue
907-261-3109
kwilsack@provak.org

Back to Top

Location: Phoenix

Trial Title and Description:

A Phase 2a Multi-center, randomized, double blind, placebo-controlled study to investigate the efficacy and safety of T-817MAa in patients with mild to moderate Alzheimer’s Disease.

Enrollment Status: Recruiting

Study Dates: Start November, 2007 Expected Completion: November, 2011

Condition: Alzheimer’s Disease
Age Eligibility: 50 – 90 years of age
Gender Eligibility: Male or Female
Enrollment Goal: 326
Clinical Identifier: NCT00663936
Study Phase: 2a
Study Type: Interventional

Sponsor: Toyama Chemical Co. Ltd

Contact Information:
Banner Alzheimer’s Institute
Lisa Cooper
602-239-6920
www.KiokuStudy.com

Back to Top

Location: Phoenix
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy to Acetylcholinesterase Inhibitors In Mild To Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: July 2006

Condition: Alzheimer's disease
Age Eligibility: 50-85
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Stephen Flitman (for zip code 85013)
877-379-3718

Pierre Tariot (for zip code 85006- Not yet recruiting)
602-239-6920

Jeffrey Gitt (for zip code 85050)
602-288-4673

Back to Top

Location: Phoenix
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Stephen Flitman
877-379-3718

Back to Top

Location: Sun City
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy to Acetylcholinesterase Inhibitors In Mild To Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: July 2006

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Maninder Kahlon
877-379-3718

Back to Top

Location: Tucson

Trial Title and Description:

A Phase 2a Multi-center, randomized, double blind, placebo-controlled study to investigate the efficacy and safety of T-817MAa in patients with mild to moderate Alzheimer’s Disease.

Enrollment Status: Recruiting

Study Dates: Start November, 2007 Expected Completion: November, 2011

Condition: Alzheimer’s Disease
Age Eligibility: 50 – 90 years of age
Gender Eligibility: Male or Female
Enrollment Goal: 326
Clinical Identifier: NCT00663936
Study Phase: 2a
Study Type: Interventional

Sponsor: Toyama Chemical Co. Ltd

Contact Information:
Northwest NeuroSpecialists, PLLC
Dawn Brown
520-742-1833
www.KiokuStudy.com

Back to Top

Location: Tucson
University of Arizona

Trial Title and Description: Anti-Oxidant Treatment of Alzheimer's Disease-

The purpose of this study is to examine the safety and effectiveness of two anti-oxidant treatment regimens in patients with mild to moderate Alzheimer's disease. The anti-oxidant treatments include vitamin E + C + alpha-lipoic acid, and Coenzyme Q (CoQ).

Enrollment Status: Recruiting

Study Dates: Start: January 2006

Condition: Alzheimer's disease
Age Eligibility: 60-85
Gender Eligibility: Both
Enrollment Goal: 75
Clinical Identifier: NCT00117403
Study Phase: Phase 1
Study Type: Interventional

Sponsor: National Institute on Aging (NIA)

Contact Information:
Marjorie Baldwin
520-626-4296
baldwinm@u.arizona.edu

Geoffrey Ahern

Back to Top

Location: Call for details

Trial Title and Description: A study of V950 in People with Alzheimer's Disease-

The purpose of this study is to test the safety, tolerability and immune response to an investigational vaccine, V950.

Enrollment Status: Recruiting

Study Dates: Start: April 2007

Condition: Alzheimer's disease
Age Eligibility: 55 and above
Gender Eligibility: Both
Enrollment Goal: Call for details
Clinical Identifier: NCT00464334
Study Phase: Phase 1
Study Type: Interventional

Sponsor: Merck

Contact Information:
Trial Manager
888-577-8839

Back to Top

Location: Call for details

Trial Title and Description: Open-Label Extension Assessing Long Term Safety of Rosiglitazone In Subjects with Mild To Moderate Alzheimer's Disease-

This is an open-label extension to study 49653/461, to assess the long-term safety of rosiglitazone (extended release tablets) in subjects with mild to moderate Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: February 2006

Condition: Alzheimer's disease
Age Eligibility: 50-85
Gender Eligibility: Both
Enrollment Goal: 60
Clinical Identifier: NCT00381238
Study Phase: Phase 2
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
877-379-3718

Back to Top

Location: Carson

Trial Title and Description:

A Phase 2a Multi-center, randomized, double blind, placebo-controlled study to investigate the efficacy and safety of T-817MAa in patients with mild to moderate Alzheimer’s Disease.

Enrollment Status: Recruiting

Study Dates: Start November, 2007 Expected Completion: November, 2011

Condition: Alzheimer’s Disease
Age Eligibility: 50 – 90 years of age
Gender Eligibility: Male or Female
Enrollment Goal: 326
Clinical Identifier: NCT00663936
Study Phase: 2a
Study Type: Interventional
Sponsor: Toyama Chemical Co. Ltd

Contact Information:
AV Institute, Inc.
Carlos Valdes
310-329-2170
www.KiokuStudy.com

Back to Top

Location: Chula Vista
University of California, San Diego-Chula Vista

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Clydene Nee
858-622-5747

Back to Top

Location: Fresno
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy to Acetylcholinesterase Inhibitors In Mild To Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: July 2006

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline 

Contact Information:
David Margolin (for zip code 93720)
Justine Kent (for zip code 93720)
877-379-3718

Back to Top

Location: Glendale
Glendale Memorial Hospital

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Mary Eichenhofer
818-409-7653

Back to Top

Location: Irvine
University of California, Irvine

Trial Title and Description: Anti-Oxidant Treatment of Alzheimer's Disease-

The purpose of this study is to examine the safety and effectiveness of two anti-oxidant treatment regimens in patients with mild to moderate Alzheimer's disease. The anti-oxidant treatments include vitamin E + C + alpha-lipoic acid, and Coenzyme Q (CoQ).

Enrollment Status: Recruiting

Study Dates: Start: January 2006

Condition: Alzheimer's disease
Age Eligibility: 60-85
Gender Eligibility: Both
Enrollment Goal: 75
Clinical Identifier: NCT00117403
Study Phase: Phase 1
Study Type: Interventional

Sponsor: National Institute on Aging (NIA)

Contact Information:
Catherine McAdams-Ortiz
949-824-8726
cmcadams@uci.edu

Ruth Mulnard

Back to Top

Location: La Jolla
University of California, San Diego

Trial Title and Description: Anti-Oxidant Treatment of Alzheimer's Disease-

The purpose of this study is to examine the safety and effectiveness of two anti-oxidant treatment regimens in patients with mild to moderate Alzheimer's disease. The anti-oxidant treatments include vitamin E + C + alpha-lipoic acid, and Coenzyme Q (CoQ).

Enrollment Status: Recruiting

Study Dates: Start: January 2006

Condition: Alzheimer's disease
Age Eligibility: 60-85
Gender Eligibility: Both
Enrollment Goal: 75
Clinical Identifier: NCT00117403
Study Phase: Phase 1
Study Type: Interventional

Sponsor: National Institute on Aging (NIA)

Contact Information:
Mary Pay
858-622-5804
mpay@ucsd.edu

Judith Rivera
858-622-5807
jrivera@ucsd.edu

David Weisman

Back to Top

Location: La Jolla
University of California, San Diego

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Clydene Nee
858-622-5747

Back to Top

Location: La Mesa
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Jorge Porras
877-379-3718

Back to Top

Location: Loma Linda
VA Medical Center

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Kimberly A. Bluff
909-558-3107
bluffk@lom.med.va.gov

Back to Top

Location: Long Beach
VAMC Long Beach

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Francoise M. Toussaint-Jones
562-826-5755

Back to Top

Location: Los Angeles
University of California, Los Angeles

Trial Title and Description: Anti-Oxidant Treatment of Alzheimer's Disease-

The purpose of this study is to examine the safety and effectiveness of two anti-oxidant treatment regimens in patients with mild to moderate Alzheimer's disease. The anti-oxidant treatments include vitamin E + C + alpha-lipoic acid, and Coenzyme Q (CoQ).

Enrollment Status: Recruiting

Study Dates: Start: January 2006

Condition: Alzheimer's disease
Age Eligibility: 60-85
Gender Eligibility: Both
Enrollment Goal: 75
Clinical Identifier: NCT00117403
Study Phase: Phase 1
Study Type: Interventional

Sponsor: National Institute on Aging (NIA)

Contact Information:
Jenny Bardens
310-794-6191
jbardens@mednet.ucla.edu

John Ringman

Back to Top

Location: Los Angeles
University of California

Trial Title and Description: Depression in Alzheimer's Disease-

The purpose of this study is to learn whether treating individuals with Alzheimer's disease and depression with the anti-depressant medication Sertraline (Zoloft) is helpful to people with Alzheimer's disease and to their families and caregivers.

Enrollment Status: Recruiting

Study Dates: Start: July 2004

Condition: Alzheimer's disease, Depression
Age Eligibility: 18 and above
Gender Eligibility: Both
Enrollment Goal: 130
Clinical Identifier: NCT00086138
Study Phase: Phase 2, 3
Study Type: Interventional

Sponsor: National Institute of Mental Health (NIMH)

Contact Information:
Shirley Sian
323-442-7600
sian@usc.edu

Back to Top

Location: Los Angeles
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
David Trader
877-379-3718

Back to Top

Location: Newport Beach
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Philip O'Carroll
877-379-3718

Back to Top

Location: Northridge
Northridge Hospital Medical Center

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Diane M. Killian
818-885-5458

Back to Top

Location: Oceanside, CA

Trial Title and Description:
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Tolerability of Dimebon (PF-01913539) for up to 26-Weeks in Patients With Mild to Moderate Alzheimer’s Disease

To determine the safety and tolerability of Dimebon in patients with mild to moderate Alzheimer’s Disease receiving either stable background anti-dementia therapy or who are not on anti-dementia therapy

Enrollment Status: Recruiting

Study Dates: Start May 2009 Expected Completion: May 2010

Condition: Alzheimer’s Disease
Age Eligibility: 50 years of age or older
Gender Eligibility: Male or Female
Enrollment Goal: 750
Clinical Identifier:
Study Phase: 3
Study Type: Interventional

Sponsor:

Contact Information:
Excell Research, Inc.
Carmalee Worsley, Jelena Kunovac, MD
760-758-2222
cworsley@excellresearch.com

Back to Top

Location: Oceanside
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Valentin Isacescu
877-379-3718

Back to Top

Location: Palo Alto
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Natalie Rasgon
877-379-3718

Back to Top

Location: Rancho Mirage

Trial Title and Description:

A Phase 2a Multi-center, randomized, double blind, placebo-controlled study to investigate the efficacy and safety of T-817MAa in patients with mild to moderate Alzheimer’s Disease.

Enrollment Status: Recruiting

Study Dates: Start November, 2007 Expected Completion: November, 2011

Condition: Alzheimer’s Disease
Age Eligibility: 50 – 90 years of age
Gender Eligibility: Male or Female
Enrollment Goal: 326
Clinical Identifier: NCT00663936
Study Phase: 2a
Study Type: Interventional

Sponsor: Toyama Chemical Co. Ltd

Contact Information:
Southwest Institute for Clinical Research
Linda Roger RN
760-464-2124
www.KiokuStudy.com

Back to Top

Location: Rancho Mirage
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy to Acetylcholinesterase Inhibitors In Mild To Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: July 2006

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Richard Hubbard
760-773-9117

Back to Top

Location: Redondo Beach
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
George Rederich
877-379-3718

Back to Top

Location: Reseda
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Robert Hutchman
877-379-3718

Back to Top

Location: Sacramento
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy to Acetylcholinesterase Inhibitors In Mild To Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: July 2006

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
William Au
877-379-3718

Back to Top

Location: San Diego

Trial Title and Description:

A Phase 2a Multi-center, randomized, double blind, placebo-controlled study to investigate the efficacy and safety of T-817MAa in patients with mild to moderate Alzheimer’s Disease.

Enrollment Status: Recruiting

Study Dates: Start November, 2007 Expected Completion: November, 2011

Condition: Alzheimer’s Disease
Age Eligibility: 50 – 90 years of age
Gender Eligibility: Male or Female
Enrollment Goal: 326
Clinical Identifier: NCT00663936
Study Phase: 2a
Study Type: Interventional

Sponsor: Toyama Chemical Co. Ltd

Contact Information:
Pacific Research Network
Memory Center
619-294-4302
www.KiokuStudy.com

Back to Top

Location: San Diego
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
John Doria
877-379-3718

Back to Top

Location: San Francisco (University of California)

Trial Title and Description:
Interview with family member-caregiver of person with Alzheimer's

A UCSF Department of Psychiatry research team is studying how family members of people with Alzheimer's Disease make decisions about dementia research participation. Participants must be: age 18 or older, a family member-caregiver responsible for someone with Alzheimer's, and able to read and understand English. If you qualify, you will be interviewed by a research staff member about research participation. A number of standardized questionnaires will be administered. There is only one visit required. The interview lasts about three hours. We will try to make it as convenient as possible for your schedule. Monetary compensation is provided.

Enrollment Status: Recruiting

Study Dates: Start July 2008 Expected Completion: 2010

Condition: family member-caregiver of person with Alzheimer's Disease
Age Eligibility: Age 18 or over
Gender Eligibility: male or female
Enrollment Goal: 200
Clinical Identifier: CHR(IRB) # H58055-31168-02
Study Phase: N/A
Study Type: Non-interventional

Sponsor: National Institute on Aging

Contact Information:
Jenifer Young, Study Coordinator
415-476-7381
Jenifer.Young@ucsf.edu

Back to Top

Location: San Francisco

Trial Title and Description:

A Phase 2a Multi-center, randomized, double blind, placebo-controlled study to investigate the efficacy and safety of T-817MAa in patients with mild to moderate Alzheimer’s Disease.

Enrollment Status: Recruiting

Study Dates: Start November, 2007 Expected Completion: November, 2011

Condition: Alzheimer’s Disease
Age Eligibility: 50 – 90 years of age
Gender Eligibility: Male or Female
Enrollment Goal: 326
Clinical Identifier: NCT00663936
Study Phase: 2a
Study Type: Interventional

Sponsor: Toyama Chemical Co. Ltd

Contact Information:
San Francisco Clinical Research Center
Michael Miller
415-867-1944
www.KiokuStudy.com

Back to Top

Location: San Francisco
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Jerome Goldstein
877-379-3718

Back to Top

Location: Santa Rosa
Santa Rosa Memorial Hospital Regional CCOP

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Kris Haratigan
707-521-3820

Back to Top

Location: Sherman Oaks
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy to Acetylcholinesterase Inhibitors In Mild To Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: July 2006

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Jose Schuster
877-379-3718

Back to Top

Location: Torrance
Harbor UCLA Medical Center

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Marie Jackson
310-222-5339

Back to Top

Location: Upland

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Arlene J. Katchem
909-373-0381

Back to Top

Location: Call for details

Trial Title and Description: Enhancing Consent for Alzheimer's Research (BWP-AD)-

The purpose of this study is to evaluate the efficacy of an enhanced consent procedure for patients with mild-to-moderate Alzheimer's disease, and to identify factors and patient characteristics that predict the degree to which enhanced consent is more beneficial than routine consent procedures.

Enrollment Status: Recruiting

Study Dates: Start: April 2006 Expected Completion: December 2011

Condition: Alzheimer's disease
Age Eligibility: 50 and above
Gender Eligibility: Both
Enrollment Goal: 272
Clinical Identifier: NCT00453544
Study Phase: N/A
Study Type: Interventional

Sponsor: National Institute on Aging

Contact Information:
Tia Thrasher
858-535-5795
tthrasher@ucsd.edu

Luz Pinto
858-642-3682
llpinto@ucsd.edu

Back to Top

Location: Call for details

Trial Title and Description: Raloxifene for Women with Alzheimer's Disease-

The purpose of this study is to determine whether Raloxifene, a selective estrogen receptor modulator, improves cognitive function in women with Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: August 2006

Condition: Alzheimer's disease
Age Eligibility: 60 and above
Gender Eligibility: Female
Enrollment Goal: 72
Clinical Identifier: NCT00368459
Study Phase: Phase 2
Study Type: Interventional

Sponsor: National Institute on Aging (NIA)

Contact Information:
Victor Henderson
650-498-5232
asye@stanford.edu

Sheryl Lynch
317-278-8307
slynch@iupui.edu

Back to Top

Location: Call for details

Trial Title and Description: Study Evaluating GSI-953 in Healthy Young and Alzheimer's Patients-

To assess the pharmacodynamics of biomarkers amyloid beta peptide 40 and 42 (Ab40 and Ab42) in CSF, following single oral doses of GSI-953, an investigational drug, in healthy young subjects and patients with Alzheimer disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2007 Expected Completion: December 2007

Condition: Alzheimer's disease
Age Eligibility: 18 and above
Gender Eligibility: Both
Enrollment Goal: 40
Clinical Identifier: NCT00479219
Study Phase: Phase 1
Study Type: Interventional

Sponsor: Wyeth

Contact Information:
Trial Manager
clinicaltrialparticipation@wyeth.com

Back to Top

Location: Call for details

Trial Title and Description: The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients-

The aim of the proposed study is to determine if the NMDA receptor antagonist Memantine has a neuroprotective effect on magnetic resonance spectroscopic imaging (MRS) measures of brain NAA and magnetic resonance imaging (MRI) volumetric measures of hippocampal volume. In secondary analyses, we will determine if measures of clinical stabilization produced by meantime in the treatment of Alzheimer’s disease parallels stabilization of MRS measures of brain NAA and MRI volumetric measures of hippocampal volume.

Enrollment Status: Recruiting

Study Dates: Start: May 2005 Expected Completion: May 2008

Condition: Alzheimer's disease
Age Eligibility: 50-95
Gender Eligibility: Both
Enrollment Goal: 15
Clinical Identifier: NCT00255086
Study Phase: N/A
Study Type: Interventional

Sponsor: Stanford University

Contact Information:
Aimee Stepp
650-493-5000, ext. 65654
aimee.stepp@stanford.edu

Back to Top

Location: Denver

Trial Title and Description:
A Phase 2a Multi-center, randomized, double blind, placebo-controlled study to investigate the efficacy and safety of T-817MAa in patients with mild to moderate Alzheimer’s Disease.

Enrollment Status: Recruiting

Study Dates: Start November, 2007 Expected Completion: November, 2011

Condition: Alzheimer’s Disease
Age Eligibility: 50 – 90 years of age
Gender Eligibility: Male or Female
Enrollment Goal: 326
Clinical Identifier: NCT00663936
Study Phase: 2a
Study Type: Interventional

Sponsor: Toyama Chemical Co. Ltd

Contact Information:
Radiant Research
Burlleen Hewitt
303-480-7122 or cell 303-842-1227
www.KiokuStudy.com

Back to Top

Location: Denver
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy to Acetylcholinesterase Inhibitors In Mild To Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: July 2006

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Leslie Moldauer
877-379-3718

Back to Top

Location: Denver
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Jack Klapper
877-379-3718

Back to Top

Location: Fort Collins
Rocky Mountain CC/ Poudre Valley Hospital

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Linda M. Hadlow
970-495-7322

Back to Top

Location: Darien
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Bart Sloan
877-379-3718

Back to Top

Location: Hamden

Trial Title and Description: A Phase 2a Multi-center, randomized, double blind, placebo-controlled study to investigate the efficacy and safety of T-817MAa in patients with mild to moderate Alzheimer’s Disease.

Enrollment Status: Recruiting

Study Dates: Start November, 2007 Expected Completion: November, 2011

Condition: Alzheimer’s Disease
Age Eligibility: 50 – 90 years of age
Gender Eligibility: Male or Female
Enrollment Goal: 326
Clinical Identifier: NCT00663936
Study Phase: 2a
Study Type: Interventional

Sponsor: Toyama Chemical Co. Ltd

Contact Information:
Geriatric and Adult Psychiatry, LLC
Andrea DeClement
262-513-0700
www.KiokuStudy.com

Back to Top

Location: Fairfield
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Kenneth Siegal
877-379-3718

Back to Top

Location: New Haven
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy to Acetylcholinesterase Inhibitors In Mild To Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: July 2006

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Christopher Van Dyck
877-379-3718

Back to Top

Location: Norwalk

Trial Title and Description:

A Phase 2a Multi-center, randomized, double blind, placebo-controlled study to investigate the efficacy and safety of T-817MAa in patients with mild to moderate Alzheimer’s Disease.

Enrollment Status: Recruiting

Study Dates: Start November, 2007 Expected Completion: November, 2011

Condition: Alzheimer’s Disease
Age Eligibility: 50 – 90 years of age
Gender Eligibility: Male or Female
Enrollment Goal: 326
Clinical Identifier: NCT00663936
Study Phase: 2a
Study Type: Interventional

Sponsor: Toyama Chemical Co. Ltd

Contact Information:
Research Center for Clinical Studies
Bart A. Sloan, M.D.
203-838-0070
www.KiokuStudy.com

Back to Top

Location: Call for details

Trial Title and Description: Evaluation of [123I] AV83 and SPECT in Patients With Alzheimer's Disease in Comparison to Healthy Controls-

The underlying goal of this study is to assess 123-I AV83 SPECT imaging as a tool to detect B-amyloid deposition in the brain of Alzheimer's disease research participants and age- and gender-matched healthy subjects.

Enrollment Status: Recruiting

Study Dates: Start: March 2007

Condition: Alzheimer's disease
Age Eligibility: 50 and above
Gender Eligibility: Both
Enrollment Goal: 30
Clinical Identifier: NCT00448799
Study Phase: Phase 1
Study Type: Interventional

Sponsor: Institute for Neurodegenerative Disorders
Molecular NeuroImaging

Contact Information:
Elizabeth Paul
203-401-4300
epaul@indd.org

Back to Top

Location: Call for details

Trial Title and Description: Evaluation of [123I] MNI-187and SPECT in Patients With Alzheimer's Disease in Comparison to Healthy Controls-

The underlying goal of this study is to assess 123-I MNI-187 SPECT imaging as a tool to detect B-amyloid deposition in the brain of Alzheimer's disease research participants and age- and gender-matched healthy subjects.

Enrollment Status: Recruiting

Study Dates: Start: April 2007

Condition: Alzheimer's disease
Age Eligibility: 50 and above
Gender Eligibility: Both
Enrollment Goal: 30
Clinical Identifier: NCT00456417
Study Phase: Phase 1
Study Type: Interventional

Sponsor: Institute for Neurodegenerative Disorders
Molecular NeuroImaging

Contact Information:
Elizabeth Paul
203-401-4300
epaul@indd.org

Back to Top

Location: Call for details

Trial Title and Description: Evaluation of [123I] MNI-187and SPECT in Patients With Alzheimer's Disease in Comparison to Healthy Controls-

The underlying goal of this study is to assess 123-I MNI-187 SPECT imaging as a tool to detect B-amyloid deposition in the brain of Alzheimer's disease research participants and age- and gender-matched healthy subjects.

Enrollment Status: Recruiting

Study Dates: Start: April 2007

Condition: Alzheimer's disease
Age Eligibility: 50 and above
Gender Eligibility: Both
Enrollment Goal: 30
Clinical Identifier: NCT00456417
Study Phase: Phase 1
Study Type: Interventional

Sponsor: Institute for Neurodegenerative Disorders
Molecular NeuroImaging

Contact Information:
Elizabeth Paul
203-401-4300
epaul@indd.org

Back to Top

Location: Washington , DC
DC United MBCCOP

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Dionne Thorne
202-865-5398

Back to Top

Location: Washington , DC
George Washington University Medical Center

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Maria-Lourdes Caparas
202-496-6464

Back to Top

Location: Washington , DC
Silbley Memorial Hospital

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Sheila Evans
202-243-2320
sevans@sibley.org

Back to Top

Location: Call for details

Trial Title and Description: A study of V950 in People with Alzheimer's Disease-

The purpose of this study is to test the safety, tolerability and immune response to an investigational vaccine, V950.

Enrollment Status: Recruiting

Study Dates: Start: April 2007

Condition: Alzheimer's disease
Age Eligibility: 55 and above
Gender Eligibility: Both
Enrollment Goal: Call for details
Clinical Identifier: NCT00464334
Study Phase: Phase 1
Study Type: Interventional

Sponsor: Merck

Contact Information:
Trial Manager
888-577-8839

Back to Top

Location: Call for details

Trial Title and Description: PET Scanning [11C] MeS-IMPY to Measure Amyloid in Brain-

This study will use positron emission tomography (PET) to measure a protein called amyloid in the brains of healthy volunteers and people with Alzheimer's disease. The tracer used in this study is a research drug called [11C] MeS-IMPY.

Enrollment Status: Recruiting

Study Dates: Start: December 2006

Condition: Alzheimer's disease, Neurodegenerative disease, Dementia
Age Eligibility: Healthy subjects: 18-80
Alzheimer's diseases: 50-80
Gender Eligibility: Both
Enrollment Goal: 15
Clinical Identifier: NCT00407576
Study Phase: N/A
Study Type: Observational

Sponsor: National Institute of Mental Health

Contact Information:
Patient Recruitment and Public Liaison Office
800-411-1222

Back to Top

Location: Call for details

Trial Title and Description: REVEAL III: Risk Evaluation and Education for Alzheimer's Disease-

The purpose of this study is to provide healthy adults with genetic testing and information about their chances of developing Alzheimer's disease

Enrollment Status: Recruiting

Study Dates: Start: March 2007 Expected Completion: March 2010

Condition: Alzheimer's disease
Age Eligibility: 18-85
Gender Eligibility: Both
Enrollment Goal: 280
Clinical Identifier: NCT00462917
Study Phase: N/A
Study Type: Observational

Sponsor: National Human Genome Research Institute (NHGRI)

Contact Information:
Susan Hiraki
617-638-5355
shiraki@bu.edu

Back to Top

Location: Call for details

Trial Title and Description: Alzheimer's Caregiver Communication Study-

The point of this research is to improve the communicative relationship between the caregiver and care receiver. It is input from the caregiver on these communicative behaviors that will inform the process of understanding how to reduce the caregiver burden that comes from this communicative relationship.

Enrollment Status: Recruiting

Study Dates: Start: October 2004 Expected Completion: September 2007

Condition: Alzheimer's disease
Age Eligibility: 60 and above
Gender Eligibility: Both
Enrollment Goal: 140
Clinical Identifier: NCT00182988
Study Phase: N/A
Study Type: Observational

Sponsor: National Institute on Aging (NIA)

Contact Information:
Kris Gravanda
202-687-9078

Back to Top

Location: Boynton Beach

Trial Title and Description:

A Phase 2a Multi-center, randomized, double blind, placebo-controlled study to investigate the efficacy and safety of T-817MAa in patients with mild to moderate Alzheimer’s Disease.

Enrollment Status: Recruiting

Study Dates: Start November, 2007 Expected Completion: November, 2011

Condition: Alzheimer’s Disease
Age Eligibility: 50 – 90 years of age
Gender Eligibility: Male or Female
Enrollment Goal: 326
Clinical Identifier: NCT00663936
Study Phase: 2a
Study Type: Interventional

Sponsor: Toyama Chemical Co. Ltd

Contact Information:
NeuroPsychiatric Center of the Palm Beaches
Name: Jacqueline Taylor
Phone: 561-364-7257
Email: www.KiokuStudy.com

Back to Top

Location: Deerfield Beach
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Jose De La Gandara877-379-3718

Back to Top

Location: Delray Beach
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy to Acetylcholinesterase Inhibitors In Mild To Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: July 2006

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Mark Brody
877-379-3718

Back to Top

Location: Delray Beach
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Mark Brody
877-379-3718

Back to Top

Location: Destin
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Elizabeth Roberson
877-379-3718

Back to Top

Location: Hallandadle Beach
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy to Acetylcholinesterase Inhibitors In Mild To Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: July 2006

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Beth Safirstein
877-379-3718

Back to Top

Location: Hialeah
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Miguel Flores
877-379-3718

Back to Top

Location: Jacksonville
Baptist Medical Center

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Sally Coxwell
904-202-7073
sallybrci@aol.com

Back to Top

Location: Melbourne
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Thomas Hoffman
877-379-3718

Back to Top

Location: Miami
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy to Acetylcholinesterase Inhibitors In Mild To Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: July 2006

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Mario Cuervo
877-379-3718

Back to Top

Location: Miami Beach
Wien Center, Mount Sinai Medical Center

Trial Title and Description: Anti-Oxidant Treatment of Alzheimer's Disease-

The purpose of this study is to examine the safety and effectiveness of two anti-oxidant treatment regimens in patients with mild to moderate Alzheimer's disease. The anti-oxidant treatments include vitamin E + C + alpha-lipoic acid, and Coenzyme Q (CoQ).

Enrollment Status: Recruiting

Study Dates: Start: January 2006

Condition: Alzheimer's disease
Age Eligibility: 60-85
Gender Eligibility: Both
Enrollment Goal: 75
Clinical Identifier: NCT00117403
Study Phase: Phase 1
Study Type: Interventional

Sponsor: National Institute on Aging (NIA)

Contact Information:
Peggy Roberts
305-674-2424
proberts@msmc.com

Ranjan Duara

Back to Top

Location: Miami Beach
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Ranjan Duara
877-379-3718

Back to Top

Location: Naples

Trial Title and Description:

A Phase 2a Multi-center, randomized, double blind, placebo-controlled study to investigate the efficacy and safety of T-817MAa in patients with mild to moderate Alzheimer’s Disease.

Enrollment Status: Recruiting

Study Dates: Start November, 2007 Expected Completion: November, 2011

Condition: Alzheimer’s Disease
Age Eligibility: 50 – 90 years of age
Gender Eligibility: Male or Female
Enrollment Goal: 326
Clinical Identifier: NCT00663936
Study Phase: 2a
Study Type: Interventional

Sponsor: Toyama Chemical Co. Ltd

Contact Information:
Anchor Research Center
Candy Pewanick
239-643-8805
www.KiokuStudy.com

Back to Top

Location: North Palm Beach
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy to Acetylcholinesterase Inhibitors In Mild To Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: July 2006

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Walter Martinez
877-379-3718

Back to Top

Location: Ocala

Trial Title and Description: A Phase 2a Multi-center, randomized, double blind, placebo-controlled study to investigate the efficacy and safety of T-817MAa in patients with mild to moderate Alzheimer's Disease.

Enrollment Status: Recruiting

Study Dates: Start November, 2007 Expected Completion: November, 2011

Condition: Alzheimer's disease
Age Eligibility: 50-90 years of age
Gender Eligibility: Male or Female
Enrollment Goal: 326
Clinical Identifier: NCT00663936
Study Phase: 2a
Study Type: Interventional

Sponsor: Toyama Chemical Co. Ltd

Contact Information:
Renstar Medical Research
Pat Riddle
352-692-5800
www.KiokuStudy.com

Back to Top

Location: Plantation
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Richard McLean
877-379-3718

Back to Top

Location: Sarasota
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy to Acetylcholinesterase Inhibitors In Mild To Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: July 2006

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Roland Aung-din
877-379-3718

Back to Top

Location: Sunrise

Trial Title and Description: A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Safety and Efficacy Study of Oral ELND005 (AZD-103) in Alzheimer's Disease

Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study

Enrollment Status: Currently Enrolling

Study Start Date: December 2007

Expected Completion: May 2010

Condition: Men or Women aged 50-85 years with mild to moderate AD
Age Eligibility: 50 Years to 85 Years
Gender Eligibility: Both
Enrollment Goal: 340
Clinical Identifier: NCT00568776
Study Phase: II
Study Type: Interventional

Sponsor: Elan Pharmaceuticals

Contact Information:
Name: Barry J. Cutler, MD
Phone: (954) 475-8171
Email: info@neuroresearch.net

Back to Top

Location: Sunrise
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Richard Singer
877-379-3718

Back to Top

Location: Tampa, FL

 Trial Title and Description: A Phase 2a Multi-center, randomized, double blind, placebo-controlled study to investigate the efficacy and safety of T-817MAa in patients with mild to moderate Alzheimer’s Disease.

 Enrollment Status: Recruiting

 Study Dates: Start November, 2007 Expected Completion: November, 2011

Condition: Alzheimer’s Disease
Age Eligibility: 50-90 Years of age
Gender Eligibility: Male or Female
Enrollment Goal: 326
Clinical Identifier: NCT00663936
Study Phase: 2a
Study Type: Interventional

Sponsor: Toyama Chemical Co. Ltd

Contact Information:
University of South Florida
Marianne Chanti-Ketterl
Phone: (Contact phone number has changed)
www.kiokustudy.com

Back to Top

Location: Tampa

Trial Title and Description:

A Phase 2a Multi-center, randomized, double blind, placebo-controlled study to investigate the efficacy and safety of T-817MAa in patients with mild to moderate Alzheimer’s Disease.

Enrollment Status: Recruiting

Study Dates: Start November, 2007 Expected Completion: November, 2011

Condition: Alzheimer’s Disease
Age Eligibility: 50 – 90 years of age
Gender Eligibility: Male or Female
Enrollment Goal: 326
Clinical Identifier: NCT00663936
Study Phase: 2a
Study Type: Interventional

Sponsor: Toyama Chemical Co. Ltd

Contact Information:
University of South Florida
Marianne Chanti-Ketterl
813-974-4355
www.KiokuStudy.com

Back to Top

Location: Tampa

Trial Title and Description:

A Phase 2a Multi-center, randomized, double blind, placebo-controlled study to investigate the efficacy and safety of T-817MAa in patients with mild to moderate Alzheimer’s Disease.

Enrollment Status: Recruiting

Study Dates: Start November, 2007 Expected Completion: November, 2011

Condition: Alzheimer’s Disease
Age Eligibility: 50 – 90 years of age
Gender Eligibility: Male or Female
Enrollment Goal: 326
Clinical Identifier: NCT00663936
Study Phase: 2a
Study Type: Interventional

Sponsor: Toyama Chemical Co. Ltd

Contact Information:
Axiom Clinical Research of Florida
Leigh Donharl
813-353-9613
www.KiokuStudy.com

Back to Top

Location: West Palm Beach

Trial Title and Description:

A Phase 2a Multi-center, randomized, double blind, placebo-controlled study to investigate the efficacy and safety of T-817MAa in patients with mild to moderate Alzheimer’s Disease.

Enrollment Status: Recruiting

Study Dates: Start November, 2007 Expected Completion: November, 2011

Condition: Alzheimer’s Disease
Age Eligibility: 50 – 90 years of age
Gender Eligibility: Male or Female
Enrollment Goal: 326
Clinical Identifier: NCT00663936
Study Phase: 2a
Study Type: Interventional

Sponsor: Toyama Chemical Co. Ltd

Contact Information:
Premiere Research Institute
Ernesto Triana, M.D.
561-846-0500 ext 137
www.KiokuStudy.com

Back to Top

Location: Call for details

Trial Title and Description: A study of V950 in People with Alzheimer's Disease-

The purpose of this study is to test the safety, tolerability and immune response to an investigational vaccine, V950.

Enrollment Status: Recruiting

Study Dates: Start: April 2007

Condition: Alzheimer's disease
Age Eligibility: 55 and above
Gender Eligibility: Both
Enrollment Goal: Call for details
Clinical Identifier: NCT00464334
Study Phase: Phase 1
Study Type: Interventional

Sponsor: Merck

Contact Information:
Trial Manager
888-577-8839

Back to Top

Location: Call for details

Trial Title and Description: Delaying the Progression of Driving Impairment in Individuals with Mild Alzheimer's Disease-

The purpose of this study is to determine whether memantine delays the progression of driving impairment in patients with mild Alzheimer's Disease.

Enrollment Status: Not yet recruiting

Study Dates: Start: June 2007 Expected Completion: December 2009

Condition: Alzheimer's disease
Age Eligibility: 60 and above
Gender Eligibility: Both
Enrollment Goal: 60
Clinical Identifier: NCT00476008
Study Phase: Phase 4
Study Type: Interventional

Sponsor: Florida Atlantic University

Contact Information:
Linda Perez
561-297-0502

Back to Top

Location: Columbus

Trial Title and Description:

A Phase 2a Multi-center, randomized, double blind, placebo-controlled study to investigate the efficacy and safety of T-817MAa in patients with mild to moderate Alzheimer’s Disease.

Enrollment Status: Recruiting

Study Dates: Start November, 2007 Expected Completion: November, 2011

Condition: Alzheimer’s Disease
Age Eligibility: 50 – 90 years of age
Gender Eligibility: Male or Female
Enrollment Goal: 326
Clinical Identifier: NCT00663936
Study Phase: 2a
Study Type: Interventional

Sponsor: Toyama Chemical Co. Ltd

Contact Information:
Columbus Research and Wellness Institute
Anitra Coicou
706-653-0419
www.KiokuStudy.com

Back to Top

Location: Decatur
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Michael Norman
877-379-3718

Back to Top

Location: Tucker
Kaiser Southeast Permanente Medical Group

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Carol A. Mayers
770-496-3634

Back to Top

Location: Middleton
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild to Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD). RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Not yet recruiting

Study Dates: Start: January 2007

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Leslie Taylor
877-379-3718

Back to Top

Location: Fort Wayne
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy to Acetylcholinesterase Inhibitors In Mild To Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: July 2006

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Fen-lei Chang
877-379-3718

Back to Top

Location: Indianapolis

Trial Title and Description:

A Phase 2a Multi-center, randomized, double blind, placebo-controlled study to investigate the efficacy and safety of T-817MAa in patients with mild to moderate Alzheimer’s Disease.

Enrollment Status: Recruiting

Study Dates: Start November, 2007 Expected Completion: November, 2011

Condition: Alzheimer’s Disease
Age Eligibility: 50 – 90 years of age
Gender Eligibility: Male or Female
Enrollment Goal: 326
Clinical Identifier: NCT00663936
Study Phase: 2a
Study Type: Interventional

Sponsor: Toyama Chemical Co. Ltd

Contact Information:
Agewell
Lori Rawlings, RN
317-846-9792 ext. 103
www.KiokuStudy.com

Back to Top

Location: Indianapolis
GSK Clinical Trials Call Center

Trial Title and Description: Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy to Acetylcholinesterase Inhibitors In Mild To Moderate Alzheimer's Disease-

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG. This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one’s genetic makeup affects the response to the study drug.

Enrollment Status: Recruiting

Study Dates: Start: July 2006

Condition: Alzheimer's disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase 3
Study Type: Interventional

Sponsor: GlaxoSmithKline

Contact Information:
Ann Marie Hake
877-379-3718

Back to Top

Location: Call for details

Trial Title and Description: Alzheimer's Caregiver Communication Study-

The point of this research is to improve the communicative relationship between the caregiver and care receiver. It is input from the caregiver on these communicative behaviors that will inform the process of understanding how to reduce the caregiver burden that comes from this communicative relationship.

Enrollment Status: Recruiting

Study Dates: Start: June 2002 Expected Completion: May 2008

Condition: Alzheimer's disease, late onset Alzheimer's disease
Age Eligibility: 50 and above
Gender Eligibility: Both
Enrollment Goal: 3,000
Clinical Identifier: NCT00064870
Study Phase: N/A
Study Type: Observational

Sponsor: National Institute on Aging (NIA)

Contact Information:
Jessica Leatherland
800-526-2839
317-278-9546
alzstudy@iupui.edu

Valerie P. Parks

Back to Top

Location: Call for details

Trial Title and Description: Alzheimer's Caregiver Communication Study-

The point of this research is to improve the communicative relationship between the caregiver and care receiver. It is input from the caregiver on these communicative behaviors that will inform the process of understanding how to reduce the caregiver burden that comes from this communicative relationship.

Enrollment Status: Recruiting

Study Dates: Start: June 2002 Expected Completion: May 2008

Condition: Alzheimer's disease, late onset Alzheimer's disease
Age Eligibility: 50 and above
Gender Eligibility: Both
Enrollment Goal: 3,000
Clinical Identifier: NCT00064870
Study Phase: N/A
Study Type: Observational

Sponsor: National Institute on Aging (NIA)

Contact Information:
Michelle Goodman
800-526-2839
alzstudy@iupui.edu

Tatiana M. Foroud

Back to Top

Location: Call for details

Trial Title and Description: Raloxifene for Women with Alzheimer's Disease-

The purpose of this study is to determine whether Raloxifene, a selective estrogen receptor modulator, improves cognitive function in women with Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: August 2006

Condition: Alzheimer's disease
Age Eligibility: 60 and above
Gender Eligibility: Female
Enrollment Goal: 72
Clinical Identifier: NCT00368459
Study Phase: Phase 2
Study Type: Interventional

Sponsor: National Institute on Aging (NIA)

Contact Information:
Victor Henderson
650-498-5232
asye@stanford.edu

Sheryl Lynch
317-278-8307
slynch@iupui.edu

Back to Top

Location: Ames
Bliss Cancer Center/McFarland Clinic

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Janet C. Mannetter
515-239-2621
mannetter@mgmc.com

Back to Top

Location: Cedar Rapids
Cedar Rapids CCOP

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Kathy Fleming
319-363-2690

Back to Top

Location: Davenport
Genesis Medical Center

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Not yet r ecruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Cecil Runyons
859-257-1412 ext. 235
preadvise@lsu.uky.edu

Back to Top

Location: Des Moines
Iowa Oncology Research Association

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Mary Loots
515-244-7586

Back to Top

Location: Sioux City
Siouxland Hematology-Oncology Associates

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Pamela J. Mears
712-252-9334

Back to Top

Location: Kansas City
University of Kansas Medical Center

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Scott Stanley
913-588-3124
sstanley@kumc.edu

Back to Top

Location: Topeka
Stormont-Vail Health Care/Cotton O'neil Clinic

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting

Study Dates: Start: May 2002 Expected Completion: August 2013

Condition: Alzheimer's disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase 3
Study Type: Interventional

Sponsor: National Institute on Aging (NIA), National Cancer Institute (NCI)

Contact Information:
Anita S. Leonard
785-354-0540

Back to Top

Location: Wichita
Wichita CCOP

Trial Title and Description: Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)-

The Prevention of Alzheimer's disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking Selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease.

Enrollment Status: Recruiting